


Industry Symposium at IASLC 2019 World Conference on Lung Cancer

TREATMENT SEQUENCING FOR ADVANCED NSCLC

Chair: Tetsuya Mitsudomi

Sunday, 8 September, 18:00 – 19:30

Hall 8.0, Room: Hilton Head (1978)
GRAN VIA, FIRA DE BARCELONA
BARCELONA, SPAIN



This program was approved by the IASLC 2019 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2019 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

Please scan here for more information.



It is our pleasure to invite you to attend:

Treatment Sequencing for Advanced Non-Small Cell Lung Cancer

At this symposium, an international faculty of experts will discuss first-line treatment decisions for *EGFR* mutation-positive (*EGFR*M+) NSCLC and second-line treatment decisions for advanced NSCLC, including squamous cell carcinoma and non-mutated, non-squamous disease.

18:00 - 18:05

Meeting Welcome and Introductions

Tetsuya Mitsudomi

18:05 - 18:20

Maximising Time on EGFR TKI Therapy

Keunchil Park

18:20 - 18:35

Uncommon but Not Unknown: Efficacy of EGFR TKIs for Uncommon Mutations

Martin Schuler

18:35 - 18:45

Panel Discussion: First-Line Treatment Considerations for *EGFR*-Mutated NSCLC

Moderator: Tetsuya Mitsudomi

18:45 - 19:00

The Role of EGFR TKIs in the Treatment of Squamous NSCLC

David Gandara

19:00 - 19:15

NSCLC (Adenocarcinoma): The Role of Anti-Angiogenic Therapy in Overcoming Resistance to Immunotherapy

Nick Pavlakis

19:15 - 19:25

Panel Discussion: Second-Line Treatment Considerations for Advanced NSCLC

Moderator: Tetsuya Mitsudomi

19:25 - 19:30

Meeting Close

Tetsuya Mitsudomi

